# US 2017/0319493 A1 · Tamper resistant dosage forms

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0319493 A1
- Document ID: US20170319493A1
- Status: Published application
- Kind: A1
- Application number: 15/657,761
- Filed: 2017-07-24
- Published: 2017-11-09
- Earliest claimed: 2006-08-25
- Assignees: Purdue Pharma L.P.; Purdue Pharmaceuticals L.P.
- Applicants: Purdue Pharma L.P.; Purdue Pharmaceuticals L.P.
- Inventors: William H. MCKENNA; Richard O. MANNION; Edward P. O'DONNELL; Haiyong H. HUANG
- Web page: https://patentgrep.com/patent/US20170319493A1

## CPC

- A61K 9/28: Dragees; Coated pills or tablets {, e.g. with film or compression coating (A61K9/2072 takes precedence, e.g. partially coated tablets A61K9/2072, coated multilayer tablets A61K9/2086, tablets with drug-coated core A61K9/209)}
- A61J 3/005: {Coating of tablets or the like (coating of sweetmeats or confectionery A23G3/20; coating of granules in general B01J2/006)}
- A61J 3/06: into the form of pills, lozenges or dragees
- A61J 3/10: into the form of compressed tablets (tablet presses B30B11/00)
- A61K 9/0002: {Galenical forms characterised by the drug release technique; Application systems commanded by energy}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/1641: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer}
- A61K 9/2095: {Tabletting processes}
- A61K 9/284: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone}
- A61K 9/2853: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2893: {Tablet coating processes (mechanical aspects A61J3/06)}
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 29/02: without antiinflammatory effect
- B29B 7/02: non-continuous, with mechanical mixing or kneading devices, i.e. batch type
- B29B 7/88: Adding charges {, i.e. additives}
- B29C 35/045: {using gas or flames}
- B29C 35/16: Cooling {(cooling extruded material B29C48/911; cooling preforms for blow moulding B29C49/6427; cooling blown articles B29C49/66; cooling tyres during post cure inflation B29D30/0643)}
- B29C 37/0025: {Applying surface layers, e.g. coatings, decorative layers, printed layers, to articles during shaping, e.g. in-mould printing (moulding on preformed layers as inserts B29C70/68; applying fluent material to surfaces in general B05)}
- B29C 43/003: {characterised by the choice of material}
- B29C 43/02: of articles of definite length, i.e. discrete articles {(B29C35/0227 takes precedence)}
- B29C 43/52: Heating or cooling
- B29C 71/00: After-treatment of articles without altering their shape; Apparatus therefor (B29C44/56, B29C73/00 take precedence; surface shaping B29C59/00 {; for joined or sealed parts B29C66/03; after-treatment specially adapted for vulcanising tyres B29D30/0633})
- B29C 71/009: {using gases without chemical reaction (C08J7/12 takes precedence; in combination with blow-moulding B29C49/46; surface treatment using plasma B29C59/14, ionised gas B29C59/16)}
- A61K 9/2072: {characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms (A61K9/0004, A61K9/0056, A61K9/0065 take precedence)}
- B29C 2035/046: {dried air}
- B29C 2035/1658: {using gas}
- B29K 2071/02: {Polyalkylene oxides, e.g. PEO, i.e. polyethylene oxide, or derivatives thereof}
- B29K 2105/0035: {Medical or pharmaceutical agents}
- B29K 2105/251: {Particles, powder or granules (expandable particles B29K2105/046)}
- B29K 2995/0088: Molecular weight
- B29L 2031/753: {Medical equipment; Accessories therefor (bloodbags, medical bags B29L2031/7148; artificial eyes B29L2011/0008)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B29B: PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
- B29C: SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING (making preforms B29B11/00; making laminated products by combining previously unconnected layers which become one product whose layers will remain together B32B37/00 - B32B41/00)
- B29K: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR {MOULDS, } REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
- B29L: INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES

## Abstract

The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

## Claims

### Claim at position 1

1-169. (canceled)

### Claim 170

A cured shaped extended release tablet comprising:
(1) an opioid or a pharmaceutically acceptable salt thereof,
(2) at least one low molecular weight polyethylene oxide having, based on rheological measurements, an approximate molecular weight of less than 1,000,000, and
(3) at least one high molecular weight polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 7,000,000;
wherein said tablet is prepared by a process comprising the steps of:
(a) providing a first combination comprising said high molecular weight polyethylene oxide and said opioid or pharmaceutically acceptable salt thereof; and
(b) providing a second combination comprising said low molecular weight polyethylene oxide and optionally comprising said opioid or pharmaceutically acceptable salt thereof; and
(c) forming a shaped tablet comprising the first and second combinations;
(d) curing said shaped tablet by applying an air temperature from about 60° C. to about 90° C. for a time of from about 15 minutes to about 10 hours; and
(e) optionally applying one or more coatings to said shaped tablet;
wherein the total combined weight of said high and low molecular weight polyethylene oxides is at least 79% by weight, and said percent by weight is based upon the total weight of said shaped tablet, not including the combined weight of said coatings.

### Claim 171 (depends on 170)

A cured shaped tablet as defined in claim 170, wherein the percent by weight of said opioid or pharmaceutically acceptable salt is at least 2.4%, based upon the total weight of said uncoated tablet.

### Claim 172 (depends on 170)

A cured shaped tablet as defined in claim 170, wherein said time in said curing step is 15 minutes to 90 minutes.

### Claim 173 (depends on 170)

A cured shaped tablet as defined in claim 170, wherein said air temperature in said curing step is from about 70° C. to about 78° C.

### Claim 174 (depends on 170)

A cured shaped tablet as defined in claim 170, wherein
said coating, when present, is applied at least one of before or after said curing step and said coating comprises a film coating, microcrystalline cellulose, hydroxypropyl cellulose, magnesium stearate, talc, silica, fumed silica, colloidal silica dioxide, calcium stearate, carnauba wax, stearic acid, stearyl alcohol, mineral oil, paraffin, glycerin, propylene glycol, polyethylene glycol, lactose, povidone, or combinations thereof, and
said additive, when present, comprises microcrystalline cellulose, hydroxypropyl cellulose, magnesium stearate, talc, silica, fumed silica, colloidal silica dioxide, calcium stearate, carnauba wax, stearic acid, stearyl alcohol, mineral oil, paraffin, glycerin, propylene glycol, polyethylene glycol, lactose, povidone, or combinations thereof.

### Claim 175

A cured shaped extended release tablet comprising:
(1) hydrocodone or a pharmaceutically acceptable salt thereof,
(2) at least one low molecular weight polyethylene oxide having, based on rheological measurements, an approximate molecular weight of less than 1,000,000, and
(3) at least one high molecular weight polyethylene oxide having, based on rheological measurements, an approximate molecular weight of 7,000,000;
wherein said tablet is prepared by a process comprising the steps of:
(a) providing a first combination comprising said high molecular weight polyethylene oxide and said opioid or pharmaceutically acceptable salt thereof; and
(b) providing a second combination comprising said low molecular weight polyethylene oxide and optionally comprising said opioid or pharmaceutically acceptable salt thereof; and
(c) forming a shaped tablet comprising the first and second combinations;
(d) curing said shaped tablet by applying an air temperature from about 60° C. to about 90° C. for a time of from about 15 minutes to about 10 hours; and
(e) optionally applying one or more coatings to said shaped tablet;
wherein said low molecular weight polyethylene oxide is at least 20% by weight, and the total combined weight of said high and low molecular weight polyethylene oxides is at least 79% by weight, and said percent by weight is based upon the total weight of said shaped tablet, not including the combined weight of said coatings.

### Claim 176 (depends on 175)

A cured shaped tablet as defined in claim 175, wherein, said air temperature in said curing step is from about 70° C. to about 78° C.

### Claim 177 (depends on 175)

A cured shaped tablet as defined in claim 175, wherein
said coating, when present, is applied at least one of before or after said curing step and said coating comprises a film coating, microcrystalline cellulose, hydroxypropyl cellulose, magnesium stearate, talc, silica, fumed silica, colloidal silica dioxide, calcium stearate, carnauba wax, stearic acid, stearyl alcohol, mineral oil, paraffin, glycerin, propylene glycol, polyethylene glycol, lactose, povidone, or combinations thereof, and
said additive, when present, comprises microcrystalline cellulose, hydroxypropyl cellulose, magnesium stearate, talc, silica, fumed silica, colloidal silica dioxide, calcium stearate, carnauba wax, stearic acid, stearyl alcohol, mineral oil, paraffin, glycerin, propylene glycol, polyethylene glycol, lactose, povidone, or combinations thereof.

### Claim 178 (depends on 175)

A cured shaped tablet as defined in claim 175, wherein the percent by weight of said low molecular weight polyethylene oxide is at least 29% and the percent by weight of said high molecular weight polyethylene oxide is at least 50%.

### Claim 179 (depends on 175)

A cured shaped tablet as defined in claim 175, wherein said tablet comprises at least one coating, and wherein the percent by weight of said hydrocodone or pharmaceutically acceptable salt thereof is at least 2.4%, based upon the total weight of said uncoated tablet.

### Claim 180 (depends on 175)

A cured shaped tablet as defined in claim 175, wherein said tablet comprises at least one coating, and wherein the percent by weight of said hydrocodone or pharmaceutically acceptable salt thereof is at least 5%, based upon the total weight of said uncoated tablet.

### Claim 181 (depends on 175)

A cured shaped tablet as defined in claim 175, wherein said tablet comprises at least one coating, and wherein the percent by weight of said hydrocodone or pharmaceutically acceptable salt thereof is at least 10%, based upon the total weight of said uncoated tablet.

### Claim 182 (depends on 178)

A cured shaped tablet as defined in claim 178, wherein the total combined weight of said high and low molecular weight polyethylene oxides is at least 80% by weight, based upon the total weight of said uncoated tablet.

### Claim 183 (depends on 179)

A cured shaped tablet as defined in claim 179, wherein, said air temperature in said curing step is from about 70° C. to about 78° C.

### Claim 184 (depends on 175)

A cured shaped tablet as defined in claim 175, wherein said time in said curing step is 15 minutes to 90 minutes.

### Claim 185 (depends on 179)

A cured shaped tablet as defined in claim 179, wherein
said coating, when present, is applied at least one of before or after said curing step and said coating comprises a film coating, microcrystalline cellulose, hydroxypropyl cellulose, magnesium stearate, talc, silica, fumed silica, colloidal silica dioxide, calcium stearate, carnauba wax, stearic acid, stearyl alcohol, mineral oil, paraffin, glycerin, propylene glycol, polyethylene glycol, lactose, povidone, or combinations thereof, and
said additive, when present, comprises microcrystalline cellulose, hydroxypropyl cellulose, magnesium stearate, talc, silica, fumed silica, colloidal silica dioxide, calcium stearate, carnauba wax, stearic acid, stearyl alcohol, mineral oil, paraffin, glycerin, propylene glycol, polyethylene glycol, lactose, povidone, or combinations thereof.

### Claim 186 (depends on 179)

A cured shaped tablet as defined in claim 179, wherein said air temperature in said curing step is from about 70° C. to about 78° C. and said time in said curing step is 15 minutes to 90 minutes.

### Claim 187 (depends on 180)

A cured shaped tablet as defined in claim 180, wherein said air temperature in said curing step is from about 70° C. to about 78° C. and said time in said curing step is 15 minutes to 60 minutes.

### Claim 188 (depends on 179)

A cured shaped tablet as defined in claim 179, wherein the percent by weight of said high molecular weight polyethylene oxide is at least 54%, based upon the total weight of said uncoated tablet.

### Claim 189 (depends on 175)

A cured shaped tablet as defined in claim 175, wherein the total combined weight of said high and low molecular weight polyethylene oxides is at least 85% by weight, based upon the total weight of said uncoated tablet.

### Claim 190 (depends on 175)

A cured shaped tablet as defined in claim 175, wherein the total combined weight of said high and low molecular weight polyethylene oxides is at least 90% by weight, based upon the total weight of said uncoated tablet.

### Claim 191 (depends on 179)

A cured shaped tablet as defined in claim 179, wherein the total combined weight of said high and low molecular weight polyethylene oxides is at least 80% by weight, based upon the total weight of said uncoated tablet, and wherein
said coating, when present, is applied at least one of before or after said curing step and said coating comprises a film coating, microcrystalline cellulose, hydroxypropyl cellulose, magnesium stearate, and combinations thereof, and
said additive, when present, comprises microcrystalline cellulose, hydroxypropyl cellulose, magnesium stearate, or combinations thereof.

### Claim 192 (depends on 179)

A cured shaped tablet as defined in claim 179, wherein the total combined weight of said high and low molecular weight polyethylene oxides is at least 85% by weight, based upon the total weight of said uncoated tablet.

### Claim 193 (depends on 179)

A cured shaped tablet as defined in claim 179, wherein the total combined weight of said high and low molecular weight polyethylene oxides is at least 90% by weight, based upon the total weight of said uncoated tablet.

### Claim 194 (depends on 191)

A cured shaped tablet as defined in claim 191, wherein said cured shaped tablet comprises said additive selected from microcrystalline cellulose, hydroxypropyl cellulose, magnesium stearate, or combinations thereof.

### Claim 195 (depends on 194)

A cured shaped tablet as defined in claim 194, wherein said curing comprises convection curing in a convection curing device.

### Claim 196 (depends on 179)

A cured shaped tablet as defined in claim 179, wherein said curing comprises convection curing in a convection curing device and said air temperature is measured as a mean exhaust temperature of said convection curing device during said curing duration.

### Claim 197 (depends on 195)

A cured shaped tablet as defined in claim 195, wherein said air temperature is measured as a mean exhaust temperature of said convection curing device during said curing time.

### Claim 198 (depends on 175)

A cured shaped tablet as defined in claim 175, wherein said cured shaped tablet, when measured without said optional coating, has a density that is at least about 1% lower than the density of said shaped tablet prior to curing, based upon an uncoated tablet.

### Claim 199 (depends on 195)

A cured shaped tablet as defined in claim 195, wherein said cured shaped tablet has a density that is at least about 1% lower than the density of said shaped tablet prior to curing.
